SUWON, Republic of Korea, Aug. 04, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today presented preclinical data on OLX702A, an investigational therapeutic for the treatment of nonalcoholic steatohepatitis (NASH), at the 48th Korean Academy of Science and Technology (KAST) International Symposium. In the study, OLX702A reversed tissue damage in the liver in a mouse model of NASH.
- In the study, OLX702A reversed tissue damage in the liver in a mouse model of NASH.
- OLX702A is a GalNAc-conjugated asymmetric siRNA (asiRNA) that targets a novel gene which is validated as a NASH-related target based on a genome-wide association study (GWAS).
- We look forward to progressing development of OLX702A based on these encouraging preclinical data, said Dong Ki Lee, Ph.D., founder and chief executive officer of OliX Pharmaceuticals.
- OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.